CEBPA and acute myeloid leukemia: The 129 CN-AML patients were further divided into subgroups by the presence of FLT3-ITD and mutation status of NPM1 and CEBPA. Levels of MAP7 expression were compared among different subgroups (GEO accession number GSE6891) (Fig. 1C).